Abstract: A tape member of an electronic apparatus includes: double-sided adhesive tape having a releasable property by stretching; and a sheet-shaped handle member connected to the double-sided adhesive tape, a user holding the handle member when stretch-releasing the double-sided adhesive tape. The handle member is wound around the double-sided adhesive tape in a direction intersecting the longitudinal direction of the double-sided adhesive tape.

Abstract: A control apparatus includes a controller configured to acquire weather information including a wind speed on a scheduled spraying date and time at which an unmanned aircraft is to spray an agricultural chemical on a field, determine a flight altitude of the unmanned aircraft according to the wind speed, and generate a plan for spraying of the agricultural chemical by the unmanned aircraft, the plan for spraying including the determined flight altitude.

Abstract: An information processing apparatus includes a controller configured to predict a scattering range of a chemical to be sprayed onto a field by a first unmanned aircraft and control, in a case in which it is determined that the chemical will scatter near the field based on the scattering range, a three-dimensional position or a travel route of a second unmanned aircraft so that downwash of the second unmanned aircraft prevents scattering of the chemical near the field.

Abstract: Provided is a composition for scalp and hair treatment, including a menthol derivative and a prostaglandin compound having two hetero atoms at the 15 position. The composition of the present invention is effective not only for preventing dandruff and itchy scalp but also for preventing or treating hair loss, baldness, or hair thinness.

Abstract: Provided is a composition for scalp and hair treatment, comprising a menthol derivative and a prostaglandin compound having two hetero atoms at the 15 position. The composition of the present invention is effective not only for preventing dandruff and itchy scalp but also for preventing or treating hair loss, baldness, or hair thinness.

Abstract: Provided is a composition for scalp and hair treatment, comprising a menthol derivative and a prostaglandin compound having two hetero atoms at the 15 position. The composition of the present invention is effective not only for preventing dandruff and itchy scalp but also for preventing or treating hair loss, baldness, or hair thinness.

Abstract: [wherein m and n may be the same or different and each represents an integer of 1 to 3 wherein m+n is 4 or less; R1 represents —NR4R5 (wherein R4 and R5 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl or the like); R2 represents the above Formula (II), Formula (IV) or the like; A represents a single bond, —C(?O)—, —SO2—, —OC(?O)— or the like; and R3 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aralkyl or the like] Bicyclic pyrimidine derivatives represented by the above Formula (I), or quaternary ammonium salts thereof, or pharmaceutically acceptable salts thereof, or the like, are provided.

Abstract: Provided is a composition for scalp and hair treatment, comprising a menthol derivative and a prostaglandin compound having two hetero atoms at the 15 position. The composition of the present invention is effective not only for preventing dandruff and itchy scalp but also for preventing or treating hair loss, baldness, or hair thinness.

Abstract: The present invention provides a screening method of a substance which inhibits binding of a condensed purine derivative to a pancreatic ? cell or a treated product of the cell, a substance which inhibits binding of a condensed purine derivative to a protein capable of the condensed purine derivative, and a substance which inhibits the expression or enzymatic activity of a protein capable of a condensed purine derivative, which comprises using the condensed purine derivative and a pancreatic ? cell or a treated product of the cell or a protein capable of binding to the condensed purine derivative.

Abstract: [wherein m and n may be the same or different and each represents an integer of 1 to 3 wherein m+n is 4 or less; R1 represents —NR4R5 (wherein R4 and R5 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl or the like); R2 represents the above Formula (II), Formula (IV) or the like; A represents a single bond, —C(?O)—, —SO2—, —OC(?O)— or the like; and R3 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aralkyl or the like] Bicyclic pyrimidine derivatives represented by the above Formula (I), or quaternary ammonium salts thereof, or pharmaceutically acceptable salts thereof, or the like, are provided.

Abstract: A fused pyrimidine derivative is presented. The derivatie has an insulin secretion stimulating activity represented by Formula (I): {wherein R1 represents a hydrogen atom, lower alkyl, or the like; n represents an integer of 0 to 3; and X1 and X2 may be the same or different and each represents a hydrogen atom, lower alkyl, or the like; and formula (II): represents formula (III): [wherein X—Y—Z represents R2C?CR3—NR4 (wherein R2, R3 and R4 may be the same or different and each represents a hydrogen atom, lower alkyl, or the like)]}, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a compound represented by formula (I): [wherein X—Y-Z represents R5N—C?O (wherein R5 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted lower alkenyl, or substituted or unsubstituted lower alkynyl), etc; R1 and R2 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, etc; and R3 and R4 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, etc], or a pharmaceutically acceptable salt thereof.

Abstract: A condensed purine derivative represented by Formula (I): wherein X—Y-Z represents R1N—C?O or N?C—W, R2 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted alicyclic heterocyclic group or the like, n represents an integer of from 0 to 3, V1 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, V2 represents a substituted lower alkyl group or a substituted or unsubstituted aromatic heterocyclic group, and when V1 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group, and for example, X—Y-Z represents R1aN—C?O and R2 represents a substituted lower

Abstract: A compound represented by general formula (I):

Abstract: A condensed purine derivative represented by Formula (I): 1

Abstract: A medicament for the therapeutic treatment of diabetes which comprises as an active ingredient a compound represented by the general formula (I): wherein R1 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, R2 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, R3 represents a hydrogen atom, a lower alkyl group or a substituted or unsubstituted aralkyl group, X1 and X2 independently represent a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group, and the symbol “n” represents an integer of from 0 to 3, or a physiologically acceptable salt thereof.

Abstract: An electromagnetic fuel injection valve for use in an internal combustion engine includes a valve body provided with a valve seat and a valve member having an abutting part moved within the valve body by an electromagnetic actuator between a closed position where the abutting part abuts against the valve seat to interrupt supply of fuel to the engine and an open position where the abutting portion is spaced from the valve seat to permit supply of the fuel to the engine. The valve member has a metering portion which cooperates with the valve seat to define therebetween a fuel metering gap when the valve member is in the open position. The abutting part of the valve member is located downstream of the metering portion with reference to a flow direction of the fuel so that the metering portion is always immersed in the fuel when the valve member is in the closed position.

Abstract: An electromagnetic fuel injection valve for use in an internal combustion engine includes a valve body provided with a valve seat and a valve member having an abutting part moved within the valve body by an electromagnetic actuator between a closed position where the abutting part abuts against the valve seat to interrupt supply of fuel to the engine and an open position where the abutting portion is spaced from the valve seat to permit supply of the fuel to the engine. The valve member has a metering portion which cooperates with the valve seat to define therebetween a fuel metering gap when the valve member is in the open position. The abutting part of the valve member is located downstream of the metering portion with reference to a flow direction of the fuel so that the metering portion is always immersed in the fuel when the valve member is in the closed position.

Abstract: An electromagnetic fuel injection valve for use in an internal combustion engine includes a valve body provided with a valve seat and a valve member having an abutting part moved within the valve body by an electromagnetic actuator between a closed position where the abutting part abuts against the valve seat to interrupt supply of fuel to the engine and an open position where the abutting portion is spaced from the valve seat to permit supply of the fuel to the engine. The valve member has a metering portion which cooperates with the valve seat to define therebetween a fuel metering gap when the valve member is in the open position. The abutting part of the valve member is located downstream of the metering portion with reference to a flow direction of the fuel so that the metering portion is always immersed in the fuel when the valve member is in the closed position.

Abstract: A new compound designated KS-505 having amnesia-inhibiting activity may be prepared by fermentation of a suitable strain of Streptomyces, preferably Streptomyces argenteolus A-2 (FERM BP-2065).